Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Applied Therapeutics
Biotech
Applied Tx's stock drops on non-update for rare disease asset
The biotech’s stock has fallen nearly 50% from its previous close of $1.24 per share, currently resting at $0.66 as of 10:45 a.m. ET this morning.
Gabrielle Masson
Sep 29, 2025 10:57am
BMS banks on Wall Street vet for strategy— Chutes & Ladders
Jun 20, 2025 8:30am
Applied's rare disease drug suffers another phase 3 failure
May 19, 2025 7:20am
Applied CEO steps down in wake of FDA rejection, warning letter
Dec 20, 2024 12:51pm
Lawsuit alleges Applied misled investors before FDA rejection
Dec 19, 2024 7:34am
FDA chides Applied Therapeutics' trial conduct in warning letter
Dec 4, 2024 11:21am
